Reversal of TGF-β-induced epithelial–mesenchymal transition in hepatocellular carcinoma by sorafenib, a VEGFR-2 and Raf kinase inhibitor

The epithelial–mesenchymal transition (EMT) is considered an essential process for cancer development and metastasis. Sorafenib, a RAF kinase and VEGFR-2 inhibitor, exhibits efficacy against advanced hepatocellular carcinoma (HCC), renal carcinoma, and thyroid cancer. It is well established that tra...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Siddharth J. Modi, Anshuly Tiwari, Vithal M. Kulkarni
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2021-01-01
Edice:	Current Research in Pharmacology and Drug Discovery
Témata:	Sorafenib Epithelial–mesenchymal transition E-cadherin Vimentin SNAIL
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2590257121000018
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!